Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

リアルタイムの更新： Satsuma Pharmaceuticals [STSA]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
最終更新日時8 6月 2023 @ 05:00
25% discount on Stockinvest.us - Use code: Podcast

0.00% $ 1.100

Live Chart Being Loaded With Signals

Commentary (8 6月 2023 @ 05:00):
Profile picture for Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...

Stats
本日の出来高 1.83M
平均出来高 1.11M
時価総額 36.47M
EPS $0 ( 2024-03-26 )
次の収益日 ( $0 ) 2024-05-09
Last Dividend $0.200 ( 2014-03-28 )
Next Dividend $0 ( N/A )
P/E -0.553
ATR14 $0.0510 (4.64%)
Insider Trading
Date Person Action Amount type
2023-06-08 Ra Capital Management, L.p. Sell 5 914 252 Common Stock
2023-06-08 Ra Capital Management, L.p. Sell 10 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 20 000 Stock Option (Right to Buy)
2023-06-08 Ra Capital Management, L.p. Sell 30 000 Stock Option (Right to Buy)
2023-06-06 O'neil Thomas P. Sell 13 877 Common Stock, $0.0001 par value
INSIDER POWER
54.69
Last 97 transactions
Buy: 62 291 817 | Sell: 17 994 879

ボリューム 相関

長: 0.14 (neutral)
短: 0.49 (neutral)
Signal:(60.819) Neutral

Satsuma Pharmaceuticals 相関

10 最も正の相関
NRBO0.956
DLTH0.937
NXTC0.934
TFFP0.933
TOI0.93
AGLE0.923
PRTK0.923
VIAV0.917
ONCS0.914
SGRP0.914
10 最も負の相関
AGFS-0.944
APEN-0.938
PRDO-0.932
NRIM-0.92
FANH-0.916
VLYPO-0.916
UFPT-0.916
MACK-0.914
TSBK-0.91
AMRB-0.906

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Satsuma Pharmaceuticals 相関 - 通貨/商品

The country flag 0.31
( neutral )
The country flag 0.35
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag -0.25
( neutral )
The country flag 0.12
( neutral )

Satsuma Pharmaceuticals 財務諸表

Annual 2022
収益: $0
総利益: $0 (0.00 %)
EPS: $-2.16
FY 2022
収益: $0
総利益: $0 (0.00 %)
EPS: $-2.16
FY 2021
収益: $0.00
総利益: $0.00 (0.00 %)
EPS: $-1.623
FY 2020
収益: $0.00
総利益: $0.00 (0.00 %)
EPS: $-2.73

Financial Reports:

No articles found.

Satsuma Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

Satsuma Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A
Information
First Dividend $0.150 2012-12-19
Last Dividend $0.200 2014-03-28
Next Dividend $0 N/A
Payout Date 2014-04-15
Next Payout Date N/A
# dividends 7 --
Total Paid Out $1.500 --
Avg. Dividend % Per Year 0.00% --
Score 1.57 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
 (2024-06-10)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
1.57
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-1.0861.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM1.3391.50010.0010.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM7.440.80010.008.00[1 - 3]
quickRatioTTM7.090.80010.008.00[0.8 - 2.5]
cashRatioTTM3.351.50010.0010.00[0.2 - 2]
debtRatioTTM0.00267-1.5009.96-10.00[0 - 0.6]
interestCoverageTTM107.961.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
freeCashFlowPerShareTTM-1.1172.00-0.559-1.117[0 - 20]
debtEquityRatioTTM0.00308-1.5009.99-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-318.091.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score3.51

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.7731.000-0.1790[1 - 100]
returnOnEquityTTM1.3392.501.15210.00[0.1 - 1.5]
freeCashFlowPerShareTTM-1.1172.00-0.372-1.117[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-1.1132.00-0.371-0.742[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.005341.500-3.300[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-0.623

Satsuma Pharmaceuticals

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。